This event has passed
Date and Location
Susan Gill
The emergence of drug-resistant bacteria is a huge and threatening problem, yet the pharmaceutical and venture capital industries have not stepped forward to address it. Why is that, and what can be done from a public policy point of view? Hear from experts who are on the front lines of antibiotic development.
This study group / discussion is open to all. Registration is not necessary.
M-RCBG welcomes individuals with disabilities to participate in its programs. To request accommodations or ask questions about access provided, please email: mrcbg@hks.harvard.edu
Speakers and Presenters
Eric Evans: M-RCBG Senior Fellow
M. Kevin Outterson: Executive Director, CARB-X (Combating Antibiotic-Resistant Bacteria)
Martin F. Heidecker: Chief Investment Officer, AMR Action Fund